Provided by Tiger Fintech (Singapore) Pte. Ltd.

ReShape Lifesciences, Inc.

0.3097
-0.0534-14.71%
Post-market: 0.30990.0002+0.06%19:58 EDT
Volume:4.48M
Turnover:1.42M
Market Cap:3.49M
PE:-0.02
High:0.3606
Open:0.3500
Low:0.3016
Close:0.3631
Loading ...

Company Profile

Company Name:
ReShape Lifesciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
18
Office Location:
18 Technology Drive,Suite 110,Irvine,California,United States
Zip Code:
92618
Fax:
- -
Introduction:
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

Directors

Name
Position
Dan Gladney
Executive Chairman
Paul Hickey
President and Chief Executive Officer and Director
Arda Minocherhomjee
Director
Gary D. Blackford
Director
Lori McDougal
Director

Shareholders

Name
Position
Paul Hickey
President and Chief Executive Officer and Director
Thomas Stankovich
Chief Financial Officer
Dan Gladney
Executive Chairman